Related Experiment Video
Updated: Jul 10, 2026

Rat Model of Photochemically-Induced Posterior Ischemic Optic Neuropathy
Published on: November 29, 2015
Arteritic anterior ischemic optic neuropathy secondary to immune checkpoint inhibitors: A case report
Zahin Alam1, Tausif Ahmed Siddiqui2, Mohammed Usman Syed2
1Department of Radiology, Hackensack Meridian School of Medicine, Nutley, NY, USA.
Abstract:
Ischemic optic neuropathy (ION) occurs due to insufficient blood supply to the optic nerve, with anterior ischemic optic neuropathy (AION) commonly associated with giant cell arteritis (GCA). Immune checkpoint inhibitors (ICIs), used in cancer therapy, have been linked to neuro-ophthalmic immune-related adverse events (irAEs), though the development of arteritic anterior ischemic optic neuropathy (AAION) due to ICI therapy is exceptionally rare. This case report describes a 77-year-old male with metastatic renal cell carcinoma on ICI therapy who presented with bilateral vision loss and was diagnosed with AAION. MRI findings supported GCA-AAION with orbital involvement, and the patient showed immediate but partial improvement with corticosteroids, despite a nonconfirmatory temporal artery biopsy. This case underscores the need for heightened clinical awareness of ICI-associated ocular complications and highlights the challenges in diagnosing and managing ICI-induced AAION, emphasizing the need for further research into treatment strategies to mitigate irreversible vision loss.
Insights
This case report details a rare instance of arteritic anterior ischemic optic neuropathy (AAION) in a patient undergoing cancer therapy with immune checkpoint inhibitors (ICIs). It highlights the critical need for recognizing ICI-induced ocular complications and improving management strategies.
Area of Science:
- Ophthalmology
- Oncology
- Neurology
Background:
- Ischemic optic neuropathy (ION) results from reduced optic nerve blood supply, with anterior ischemic optic neuropathy (AION) often linked to giant cell arteritis (GCA).
- Immune checkpoint inhibitors (ICIs) are used in cancer treatment and can cause neuro-ophthalmic immune-related adverse events (irAEs).
Observation:
- A 77-year-old male with metastatic renal cell carcinoma on ICI therapy experienced bilateral vision loss.
- Clinical presentation and MRI findings suggested GCA-associated AAION with orbital impact.
Findings:
- The patient received corticosteroids, leading to immediate but incomplete visual recovery.
- A temporal artery biopsy was nonconfirmatory, complicating the diagnosis.
Implications:
- This case emphasizes the importance of clinical vigilance for ICI-associated ocular complications, particularly the rare AAION.
- Challenges in diagnosing and managing ICI-induced AAION necessitate further research into effective treatment protocols to prevent permanent vision loss.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy

